Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 82

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 82
---
 financing activity in the condensed consolidated statement of cash flows in accordance
with ASC 230, Statement of Cash Flows. As of September 30, 2025, the value of Stella’s Series D Preferred Stock received
was determined to be $500,000, based on the subsequent sale of the 1,000,279 Stella Series D Preferred Stock for $500,000 in cash, pursuant
to Stock Purchase Agreements dated August 20, 2025.

On June 5, 2025, we sold
an additional 938 shares of Series D Preferred Stock for gross cash proceeds of $750,400 in an additional closing of the Fourth PIPE Financing.
On June 25, 2025, we entered into an amendment (the “Amendment”) to the Fourth Securities Purchase Agreement pursuant to which
the Company added certain new institutional investors to the schedule of buyers in the Fourth Securities Purchase Agreement, to issue
and sell to such investors, in one or more closings shares of the Company’s Series D Preferred Stock. Also, on June 25, 2025, we
sold an additional 2,315 shares of Series D Preferred Stock for gross cash proceeds of $1,852,000 in an additional closing of the Fourth
PIPE Financing. On July 18, 2025, the Company sold an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600
in an additional closing, and the Company received net proceeds of $320,801.

Each additional closing of
the PIPE Financings is at the option of the investors upon notice to the Company and subject to satisfaction of customary closing conditions.
Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that
sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings
with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation
of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of
operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within
one year from the date these accompanying financial statements are issued. The accompanying financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of this uncertainty.

Recent Develop